News about Clinical Trials

Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss

Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.

Clinical Trials | 04/02/2026 | By News Bureau |  242

Avobis Bio to Present Expanded STOMP2 Trial Data on AVB-114 at ECCO Congress

Expanded STOMP2 trial data highlight sustained safety and efficacy of AVB-114, as Avobis Bio prepares for Phase III development in Crohn’s disease.

Clinical Trials | 30/01/2026 | By News Bureau |  153

SK Bioscience Begins Study of Sarbecovirus Vaccine

SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.

Clinical Trials | 30/01/2026 | By News Bureau

Boehringer Ingelheim's Apecotrep Cuts Proteinuria by 40 percent in Phase II Trial for Rare Kidney Disease FSGS

Phase II data show apecotrep, a first-in-class oral TRPC6 inhibitor, significantly reduced proteinuria in patients with primary FSGS, supporting ongoing Phase III development.

Clinical Trials | 29/01/2026 | By News Bureau |  142

QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer

ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.

Clinical Trials | 29/01/2026 | By News Bureau |  122

Eisai Submits EMA Application for Once-Monthly Maintenance Dosing of Alzheimer's Drug Lecanemab

BioArctic partner Eisai has filed a Marketing Authorisation Variation with the EMA seeking approval for a once-every-four-weeks IV maintenance dosing regimen for lecanemab in early Alzheimer’s disease.

Clinical Trials | 27/01/2026 | By News Bureau

FIU Researchers Advance Functional Precision Medicine for Hard to Treat Cancers

FIU researchers are advancing functional precision medicine for hard-to-treat cancers, with new funding accelerating drug sensitivity testing to identify personalized, effective therapies beyond conventional genetic approaches.

Clinical Trials | 22/01/2026 | By News Bureau |  127

Moderna and Merck Show Durable Five-Year Benefit for Intismeran-KEYTRUDA in Melanoma

At a median five-year follow-up, intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 49 percent versus KEYTRUDA alone, with further data expected and multiple late-stage trials ongoing across tumour types.

Clinical Trials | 22/01/2026 | By News Bureau

Olatec Therapeutics Presents Promising Preclinical Data for Dapansutrile in Parkinson's Disease at MJFF Forum

Olatec Therapeutics presented MJFF-funded preclinical data showing its oral NLRP3 inhibitor dapansutrile delivered disease-modifying effects across two translational Parkinson’s disease mouse models.

Clinical Trials | 21/01/2026 | By News Bureau |  190

Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme

Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.

Clinical Trials | 20/01/2026 | By News Bureau |  231